Professional Documents
Culture Documents
Breast Cancer Screening
Breast Cancer Screening
Breast Cancer Screening
• As per Globacan data 2020, in india BC accounted for 13.5% of all cancers
and 10.6% of all cancers death.
• One in 28 women is likely to develop breast cancer during her life time.
• It involves the women herself looking at and feeling each breast for
possible lump, distortion or swelling.
• According ACS and other guidelines it should be started from late teens
or early 20s.
Although 3D mammography is
superior than 2D
mammography, ACS screening
recommendations believes that
women should be able to
choose between 2D or 3D
mammogram pertaining to its
high cost and rare availability.
High cost of 3D mammogram
is also not covered by
insurance.
USG breast/ Sonomammography
Guidelines
• WHO
• NCCN
• ACOG
• National cancer institute
• Association of breast surgeon
• American cancer society
• US preventive task force
ACS screening recommendation for women
at high risk
Annual breast MRI and mammogram, typically starting 30 years of age.
• High risk women are-
1. Known BRCA1 BRCA2 gene mutation.
2.First degree relative with BRCA1 BRCA2 mutation, and have not
had genetic testing themselves.
3. Personal h/o radiation therapy to chest wall ,age between 10 to 30
years.
4. Have 20 to 25% higher chance of developing BC according to risk
assessment tool.
5. Have Li-Fraumeni syndrome, Cowden syndrome, bannayan –Riley
Ruvalcaba syndrome or first degree relative with one of these
syndrome .
• ACS recommends against MRI screening for women whose life
time risk of breast cancer is <15%.
• No recommendation against MRI in higher lifetime risk based on
certain factors ,such as
1. personal h/o breast cancer, ductal or lobular carcinoma in
situ, atypical ductal or lobular hyperplasia.
2. having extremely or heterogenously dense breast as seen
on mammogram.
Screening in special cases
• Before initiation of hormone replacement therapy for
premature menopause or menopausal hormonal
therapy ,screening for breast cancer should be done…as
estrogen hormone can potentiate malignant lesions in breast.